Skip to main content
. 2017 Feb 12;10(1):24. doi: 10.3390/ph10010024

Figure 5.

Figure 5

Tumour volume and Kaplan-Meier survival curve of mice treated with TMZ combined with CX-4945; (A) Tumour volumes (recorded at days 6, 11, 14, 17, 19 and 21 p.i.) of control GL261 implanted mice (n = 6, blue line) and combined TMZ-CX-4945 cycles in GL261 implanted mice (n = 5, red line). The dashed blue line indicates TMZ and CX-4945 therapy start point. No significant differences were observed between groups for comparisons of control and treated mice tumour volumes at each time point (p > 0.05). C984 has been excluded from tumour volume comparisons because it has been proven an outlier with Grubb’s and Dixon’s tests; (B) Survival Kaplan-Meier curves for TMZ and CX-4945 treated mice (n = 6) and control mice (n = 6). No significant differences were found between groups (p > 0.05). The dashed blue line indicates TMZ and CX-4945 therapy start point.